Stifel Healthcare Conferenceat 2:45 p.m. ETon Tuesday, November 13, 2018in New York, NY; and
- 27th Annual
Credit Suisse Healthcare Conferenceat 10:20 a.m. MSTon Thursday, November 15, 2018in Scottsdale, AZ; and
- 30th Annual
Piper Jaffray Healthcare Conferenceat 8:00 a.m. ETon Tuesday, November 27, 2018in New York, NY.
The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company’s website. Please check www.akceatx.com for the latest information.
A live webcast of all presentations will be available on the “Media & Investors” section of the Akcea website. The replay will be available within 48 hours and will be archived for a limited time.
This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc. Any statement describing Akcea’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akcea’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea’s programs are described in additional detail in its quarterly report on Form 10-Q and other documents, which are on file with the SEC.
In this press release, unless the context requires otherwise, “Akcea,” “Company,” “we,” “our,” and “us” refers to Akcea Therapeutics.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™, TEGSEDI™ and WAYLIVRA™ are trademarks of Akcea Therapeutics, Inc.
Investor and Media Contact:
Vice President of Communications and Investor Relations
T: +1 617 207 8509